Glucosamine, commonly consumed for the treatment of osteoarthritis, is classified as a nutritional supplement; however, there are few data regarding its metabolic or vascular effects. Glucosamine is a component of the hexosamine pathway, which has been implicated in the development of insulin resistance. Anecdotal reports suggest that glucosamine consumption can increase circulating cholesterol concentrations. To investigate the metabolic and vascular effects of glucosamine supplementation, we studied male and female LDL receptor-deficient mice fed a Western diet (21% fat, 0.15% cholesterol). Three groups of 6-10 mice of each gender received either no supplement, 15 mg Á kg 21 Á d However, after 20 wk of treatment, cholesterol and triglyceride concentrations increased further in male mice consuming glucosamine compared with control groups. Glucosamine-supplemented mice had increased initiation of atherosclerosis after 5 wk; however, there was no effect on progression of atherosclerosis in either gender after longer periods of glucosamine supplementation (10 or 20 wk). Although long-term glucosamine supplementation exacerbated the hyperlipidemia in male mice, no increase in atherosclerosis occurred. Thus, glucosamine supplementation appears to be safe, with no adverse vascular consequences.
Introduction
Glucosamine is an aminosugar that plays a variety of roles in human health and metabolism. Glucosamine can be synthesized from glucose and is an essential component of glycosaminoglycans and mucopolysaccharides, which are components of connective tissue, skin, tendons, and cartilage. Although several trials suggest that glucosamine sulfate is efficacious in improving symptoms and reducing joint space narrowing of osteoarthritis of the knee (1) (2) (3) (4) , the recent glucosamine/chondroitin arthritis intervention trial using glucosamine HCl did not show significant benefits (5) . However, glucosamine is available over-thecounter, is well tolerated, and is relatively inexpensive, resulting in widespread consumption by the American public. Because glucosamine is classified as a nutritional supplement, it is subject to minimal regulation by monitoring boards, and its effects on other chronic diseases as well as metabolic outcomes have not been well studied.
Endogenously synthesized glucosamine is a key component of the hexosamine pathway, which is thought to be a mechanism by which cells sense ambient glucose concentrations (6) (7) (8) (9) . In a variety of cell culture and animal models, administration of high doses of glucosamine has been shown to induce insulin resistance (10) (11) (12) . However, doses commonly consumed by humans do not appear to increase insulin resistance (5, 13) . Another area of concern regarding glucosamine consumption is its potential effect on lipid metabolism; in the lay press, there are several reports of glucosamine supplementation leading to increased cholesterol concentrations (14-16). The Danish Medical Association has recently posted a concern regarding the effect of glucosamine in raising cholesterol concentrations and is gathering data (17) . High cholesterol concentrations and insulin resistance are both recognized risk factors for the development of atherosclerosis and cardiovascular disease. Given that most people who choose to supplement glucosamine do so over long periods of time, the effects of glucosamine to raise insulin resistance and/or cholesterol could result in increased atherosclerosis development.
Conversely, glucosamine consumption could alter the structure of the vascular wall in a manner that could decrease atherosclerosis. Glucosamine is a precursor for the synthesis of proteoglycans, a complex group of heterogeneous extracellular matrix molecules. Proteoglycans in the artery wall play a key role in the development of atherosclerosis due to their ability to bind and retain atherogenic lipoproteins in the arterial wall (18) . Proteoglycans bind lipoproteins via ionic interactions between the negatively charged sulfate and carboxyl groups on the glycosaminoglycans and positively charged amino acid residues on the lipoproteins. We previously found that proteoglycans synthesized by vascular smooth muscle cells in vitro in the presence of glucosamine are smaller, with shorter glycosaminoglycan chains, reduced sulfate incorporation, and decreased lipoprotein binding affinity (19) . A recent study found that glucosamine stimulated increased heparan sulfate proteoglycan synthesis by endothelial cells and smooth muscle cells and also inhibited smooth muscle cell proliferation (20) . If glucosamine has similar effects to modulate vascular proteoglycan synthesis in vivo, then it could be protective against atherosclerosis development, as suggested by a recent study that demonstrated decreased atherosclerosis in apoE-deficient mice given intraperitoneal glucosamine for 8 wk (20) .
The purpose of this study was to determine whether chronic glucosamine supplementation altered atherosclerosis development in mice. A major focus was to characterize metabolic parameters in mice receiving chronic glucosamine supplementation. The LDL receptor-deficient (LDLR2/2) mouse was selected for this study, because similar to humans, it carries the majority of its cholesterol in LDL particles, is susceptible to dietinduced hyperlipidemia, and develops lesions of early atherosclerosis when fed an atherogenic (Western) diet (21, 22) .
Materials and Methods
Animal model. LDLR2/2 mice were purchased from Jackson Laboratories. Mice were separated into groups of 5 and were enrolled in the study at different times to ensure robust and reliable data. This project was approved by the Animal Care and Use Committees of the University of Washington and the University of Kentucky. Because gender-specific differences in atherosclerosis have been reported (23-25), we studied both genders and analyzed data in a gender-specific manner. Mice were housed in temperature controlled (25°C) vivarium facilities with 12-h light/dark cycles. Mice consumed normal mouse chow (18% protein, 5% fat; TD2018, Harlan Teklad) ad libitum until 8 wk of age, when they were switched to a Western diet [21.2% (by weight) fat, 0.15% cholesterol, 17.3% protein] (26) (TD88137, Harlan Teklad). Diets were stored in air-tight bags at 220°C and aliquots were removed as needed. Anesthetized mice were killed at the indicated intervals by cervical dislocation.
Glucosamine supplementation. Supplemental glucosamine HCl (Sigma) was added to the drinking water at concentrations to achieve 3 doses: no added glucosamine (control), 15 mg Á kg 21 ]-glucosamine carried in water with 50 mg/kg unlabeled glucosamine, in the same total volume. Mice were bled 2 or 4 h after gavage for detection of radioactivity in plasma and were killed 24 h postgavage. Tissues were homogenized in a 1-mL volume and subject to liquid scintillation counting. Results are expressed as Bq/mg wet weight of tissue. Plasma radioactivity was determined by liquid scintillation counting of 25 mL of plasma.
Metabolic analyses. All food was removed 4 h prior to collection of blood from the retro-orbital sinus and samples were obtained in all mice at baseline and study end. Mice in the 20-wk group also had a sample obtained after 10 wk. Plasma cholesterol concentrations were determined by using a colorimetric kit (kit 234-99, Diagnostic Chemicals) and cholesterol standards (Boehringer Mannheim). Plasma triglyceride concentrations were determined colorimetrically after removal of free glycerol (kit 450032). The lipoprotein cholesterol profile was determined for 3-6 mice per group on mouse plasma separated by FPLC (27) . Glycated hemoglobin was quantified using a commercial kit (kit G7540, Pointe Scientific). Plasma glucose concentrations were determined by the Trinder method (kit G7521, Pointe Scientific) and insulin concentrations were measured by ELISA (kit 10-1149, Mercodia). To estimate insulin resistance, the HOMA index (the homeostasis model assessment for insulin resistance) was calculated using the equation [glucose (mg/dL) Á insulin (mIU/mL)/405] (28, 29).
Atherosclerosis analysis. Fatty streaks were quantified by evaluation of oil red O stained lesions in the aortic sinus, as described previously (22) . Briefly, 9 sections (10 mm thick) per mouse obtained throughout the aortic sinus (400mm) were stained with oil red O, counterstained with Harris' hematoxylin, and the lesion area was quantified using computer assisted morphometry (Image-Pro software, Media Cybernetics). Aortic surface lesions were analyzed on aortas cleaned of fat and adventitia and cut open along the greater curvature (30) . Lesion area was determined by computer assisted morphometry and quantified using ImagePro software (31) .
Evaluation of proteoglycan synthesis ex vivo. To determine the effects of oral glucosamine on vascular proteoglycan synthesis, the aortas were removed from 5 female mice per group after 5 wk of glucosamine, and 3 female mice per group after 20 wk of glucosamine (0 mg Á kg 21 4 . After 24 h, the culture medium were collected in the presence of protease inhibitors, as previously described (19) . Aortic rings were washed with saline then homogenized in 1 mL of 4 mol/L guanidine-HCl buffer. Proteoglycan synthesis was evaluated by determination of [ 35 S]-SO 4 incorporation by cetyl pyridinium chloride incorporation (32) . Secreted proteoglycans were purified on DEAE-Sephacel minicolumns and proteoglycan size and distribution was evaluated by SDS-PAGE, as previously described (19) .
Statistical analysis. Data are reported as mean 6 SEM. Absorption of [ 14 C]-glucosamine was compared by t test. Other data were tested using 2-way ANOVA (glucosamine supplementation group and time) within each gender, with multiple pairwise comparisons performed using the Holm-Sidak method. We tested variances for homogeneity and performed analyses as suggested by the statistical package (SigmaStat). Differences with ,0.05 were regarded as significant. The 5-wk atherosclerosis studies were performed first at the University of Washington then repeated at the University of Kentucky. Data from the 2 institutions were compared by 2-way ANOVA (glucosamine supplementation and institution) and were found not to differ; thus, all 5-wk data were pooled.
Results
Tolerance of glucosamine. Glucosamine was well tolerated. Water intake did not differ between mice receiving glucosamine or control mice (data not shown). Body wt and hepatic weight did not differ between the mice receiving glucosamine and control mice of the same gender at any time (data not shown). No adverse effects from glucosamine supplementation were seen. Glucosamine absorption was proportionally increased in the group receiving 50 mg Á kg 21 appeared to be mainly distributed to kidney and liver, with lower concentrations in heart and aorta, by 24 h after administration ( Table 1 ). The amount of [ 14 C]-glucosamine entering the aorta did not increase with the higher dose; however, other tissues did show a proportional increase in [
14 C]-glucosamine distribution (P , 0.05; Table 1 ).
Metabolic effects of glucosamine. Initiation of the Western diet caused significant elevations in plasma cholesterol (P , 0.001) and triglyceride concentrations (P , 0.001) in both female and male mice compared with baseline concentrations (Table 2) . However, in male mice only, plasma cholesterol concentrations were higher (P , 0.01) in mice receiving glucosamine compared with control mice after 20 wk, with a similar trend for an increase in plasma triglyceride concentrations (P ¼ 0.06), suggesting that prolonged glucosamine consumption exacerbated the dyslipidemia. Analysis of the lipoprotein cholesterol distribution profile of male mice after 20 wk of diet and glucosamine treatments demonstrated that this increase in cholesterol and triglycerides was primarily due to an increase in the VLDL fraction in mice receiving glucosamine compared with control mice (data not shown). In female mice, there were no differences in total cholesterol or triglyceride concentrations between mice receiving glucosamine and control mice at any point ( Table 2 ). The lipoprotein distribution profile did not vary between groups at any time in female mice, nor in male mice at the earlier time points (data not shown).
Similar to the effect of the Western diet on circulating lipids, the initiation of the Western diet increased glucose, insulin, and glycated hemoglobin concentrations and the HOMA index (all P , 0.002) in both female and male mice compared with baseline ( Table 3) . Glucose, insulin, or glycated hemoglobin concentrations and the HOMA index did not differ between mice receiving glucosamine and control mice at any point.
Effect of glucosamine on atherosclerosis. There was a progressive increase in atherosclerosis lesion area over time in both female and male mice (P , 0.001 for both genders). In female mice receiving glucosamine for 5 wk, there was a considerable and reproducible increase in extent of fatty streak lesion area compared with the control group ( Fig. 1A; P ¼ 0.005) . The control group differed significantly from the other 2 groups, but the glucosamine groups did not differ from one another. A similar effect was observed in male mice ( Fig. 1B; P (Fig. 1A,B) . Similarly, en face analysis of the aortic lesion area revealed no differences between mice receiving glucosamine or controls after 10 and 20 wk of diet (data not shown). In particular, there was no increase in atherosclerosis in male mice after 20 wk of glucosamine, despite the exacerbation of dyslipidemia induced by glucosamine at that time.
Effect of glucosamine on aortic proteoglycan synthesis. In female mice that received glucosamine for 5 (data not shown) or 20 wk ( Fig. 2A) , sulfate incorporation did not differ between glucosamine and control groups for either secreted or tissueassociated proteoglycans. The proteoglycans secreted by mouse aortic rings ex vivo have similar migration patterns to those seen with proteoglycans synthesized by cultured vascular smooth muscle cells (19) ; however, the size of secreted proteoglycans did not differ between glucosamine or control groups after 5 (data not shown) or 20 wk (Fig. 2B ).
Discussion
The purpose of this study was to determine whether glucosamine supplementation, at doses similar to the average human dose (on , affected atherosclerosis development and metabolic indices. We report 2 main findings from our studies. First, in both male and female LDLR2/2 mice, short term glucosamine supplementation (5 wk) significantly increased atherosclerosis initiation, but this early difference in atherosclerosis did not persist, and ultimately there was no difference in atherosclerosis progression between glucosamine and control groups. Glucosamine groups and the control group did not differ in any lipid or glycemic variable after 5 wk of glucosamine supplementation to account for this increased atherosclerosis, nor were there differences in vascular proteoglycan synthesis. Thus, the mechanism(s) by which glucosamine increases atherosclerosis initiation are not clear. Second, longterm glucosamine supplementation (20 wk) in male, but not female, mice exacerbated the diet-induced hyperlipidemia. In this study, we have confirmed previous reports that the Western diet can induce a type 2 diabetes-like phenotype in male LDLR2/2mice (26, 33) but also demonstrate increases in glucose, insulin, and glycated hemoglobin concentrations and the HOMA index in female LDLR2/2 mice. The effect of glucosamine supplementation to exacerbate the dyslipidemia in male mice but not female mice may indicate gender differences in susceptibility to adverse effects of glucosamine or may indicate an effect of glucosamine to exacerbate hyperlipidemia in the setting of insulin resistance. There is a paucity of human data examining the effects of glucosamine supplementation on lipid variables, despite several anecdotal reports in the lay press (14,15,17). The importance of this exaggerated hyperlipidemia induced by glucosamine is not clear, because despite this increase in cholesterol and triglyceride concentrations, we did not observe any differences between groups in the extent of atherosclerosis. One limitation of this interpretation may be the duration of investigation. We did not evaluate metabolic indices between 10 and 20 wk of glucosamine supplementation; thus, the duration of the increased dyslipidemia is unknown. It is possible that continued glucosamine supplementation, with continued exacerbation of dyslipidemia, may lead to increased progression of atherosclerotic lesions.
The mechanism leading to increased early atherosclerosis in glucosamine-supplemented mice compared with control mice is not clear. Our data are in opposition to a recent study that demonstrated decreased atherosclerosis after 8 wk of intraperitoneal glucosamine administration in apoE-deficient mice (20) . There are numerous differences between the studies that could account for the discrepant results, including different mice (LDLR2/2 vs. apoE2/2), different formulation of glucosamine (our study used glucosamine HCl, whereas the other study used glucosamine sulfate), dose, duration, and route of administration of glucosamine. However, our finding of increased atherosclerosis after 5 wk of supplementation was robust and reproduced in separate groups of mice enrolled at different times and in different institutions. Although we observed a robust increase in atherosclerosis initiation, this likely has low clinical impact, because human studies have shown initiation of atherosclerosis occurs at very young ages (34, 35) ; thus, most humans consuming glucosamine would already have early atherosclerotic lesions. We found no effect of glucosamine on atherosclerosis progression.
We previously reported that glucosamine supplementation (at millimolar concentrations) of vascular smooth muscle cells in vitro led to the synthesis of smaller, less sulfated proteoglycans, with reduced LDL binding affinity (19) . We hypothesized that if this effect of glucosamine to alter vascular proteoglycan synthesis existed in vivo, it would result in decreased atherosclerosis secondary to reduced retention of LDL in the arterial wall. However, when we examined the synthesis of proteoglycans ex TABLE 3 Circulating glucose, insulin, and glycated hemoglobin concentrations and the HOMA index are increased by the initiation of a Western diet but not by glucosamine supplementation in male or female LDLR2/2 mice vivo by aortic rings obtained from mice after 5 or 20 wk of glucosamine supplementation, we found no effect of glucosamine on the size of or the amount of sulfate incorporated into secreted proteoglycans. Thus, either the arterial wall concentrations of glucosamine were insufficient to induce alterations in vascular proteoglycan synthesis, or the effect of glucosamine to decrease proteoglycan size that we observed in vitro does not occur in vivo. To address this, we estimated glucosamine distribution by administering to mice proportional doses of radioactive glucosamine. We found that whereas glucosamine concentrations in the plasma, liver, kidney, and heart were proportionally increased after administration of the higher dose of [ 14 C]-glucosamine compared with the lower dose, the radioactivity localized to the aorta was not different between the doses. The concentrations of glucosamine achieved in plasma after administration of these doses could not be determined due to technological limitations in assaying the small plasma volumes obtainable in mice. However, the plasma concentrations of glucosamine achieved after oral ingestion of glucosamine have been estimated to be ,60 mmol/L (13), and in 1 study examining concentrations in 18 subjects, the highest plasma concentration was 11.5 mmol/L (36). In our previous in vitro studies, we did not observe effects on proteoglycan synthesis in vascular smooth muscle cells exposed to micromolar concentrations of glucosamine (19) . Thus, the local vascular wall concentrations of glucosamine were likely too low to affect proteoglycan synthesis in vivo, accounting for the difference between our observed results and our hypothesis that glucosamine-induced alterations in vascular proteoglycans would result in decreased atherosclerosis.
Glucosamine is classified as a supplement and is thus subject to minimal regulation by most regulatory boards. Glucosamine is widely consumed and has been for many years; thus, it is unlikely that significant toxicity results from long-term consumption. However, there are several anecdotal reports in the lay press indicating that some individuals do develop adverse metabolic effects when consuming glucosamine (14,15,17). The currently available data do not rule out an adverse effect of chronic glucosamine consumption on lipid concentrations in humans. The long-term ramifications of even a subtle increase in dyslipidemia are important. Although we found that long-term glucosamine consumption increased cholesterol and triglyceride concentrations in male mice, we did not find any adverse effect on atherosclerosis progression. Thus, the data from this study suggest that glucosamine supplementation is safe, with no longterm adverse vascular consequences. However, we caution that these data are observed in mouse atherosclerosis, and we propose that clinical trials evaluating glucosamine should include measurements of cholesterol and triglycerides, as well as evaluation of cardiovascular outcomes. 
